C4 Therapeutics (CCCC) EBIAT (2019 - 2025)
C4 Therapeutics' EBIAT history spans 7 years, with the latest figure at -$20.5 million for Q4 2025.
- For Q4 2025, EBIAT rose 40.73% year-over-year to -$20.5 million; the TTM value through Dec 2025 reached -$105.0 million, changed 0.3%, while the annual FY2025 figure was -$105.0 million, 0.3% changed from the prior year.
- EBIAT reached -$20.5 million in Q4 2025 per CCCC's latest filing, up from -$32.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$15.7 million in Q4 2021 to a low of -$37.2 million in Q4 2022.
- Average EBIAT over 5 years is -$27.7 million, with a median of -$27.2 million recorded in 2022.
- Peak YoY movement for EBIAT: plummeted 137.64% in 2022, then skyrocketed 50.68% in 2024.
- A 5-year view of EBIAT shows it stood at -$15.7 million in 2021, then crashed by 137.64% to -$37.2 million in 2022, then grew by 6.58% to -$34.8 million in 2023, then grew by 0.54% to -$34.6 million in 2024, then skyrocketed by 40.73% to -$20.5 million in 2025.
- Per Business Quant, the three most recent readings for CCCC's EBIAT are -$20.5 million (Q4 2025), -$32.2 million (Q3 2025), and -$26.0 million (Q2 2025).